Invention:
This technology is a modified version of SHU9119, a peptide chain that is known to interact with Melanocortin Receptors. This modified version of SHU9119 can antagonize a Melanocortin 5 Receptor, allowing rapidly acting drugs to target these receptors and provide therapeutic relief for those suffering from depression and other mood disorders.
Background:
Current treatments for depression include drugs with delayed therapeutic onset. This technology has the potential to alleviating depression and other moods disorders in a shorter time period.
Applications:
- Pharmaceutical compound for the treatment of depression, anxiety, and other mood disorders
Advantages:
- Targets specific receptor to minimize undesirable side effects
- May achieve therapeutic effect in less time than alternative pharmacological interventions
- Candidate for treating various mood disorders linked to anomalous Melanocortin receptor activation
Status: issued U.S. patent #9,821,023
